Previous close | 13.95 |
Open | N/A |
Bid | 8.60 |
Ask | 17.80 |
Strike | 245.00 |
Expiry date | 2024-06-28 |
Day's range | 13.95 - 13.95 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease. Eisai has also collaborated with a major Chinese medical insurance firm to plan partial coverage of the drug cost, the companies said without naming the insurer. China approved the treatment in January after a standard approval from the U.S. Food and Drug Administration last July.
China is the Third Country to Launch LEQEMBI Following the United States and JapanTOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab) has b
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.